Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Translational Development Acquisition (TDAC) Operating Expenses (2023 - 2026)

Translational Development Acquisition's Operating Expenses history spans 4 years, with the latest figure at $281161.0 for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 19.07% to $281161.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $878291.0, a 61.52% increase, with the full-year FY2025 number at $944538.0, up 381.03% from a year prior.
  • Operating Expenses came in at $281161.0 for Q1 2026, up from $162345.0 in the prior quarter.
  • The five-year high for Operating Expenses was $485550.0 in Q4 2023, with the low at $1685.0 in Q2 2024.
  • Historically, Operating Expenses has averaged $211956.3 across 4 years, with a median of $213658.0 in 2025.
  • Biggest five-year swings in Operating Expenses: plummeted 72.53% in 2024 and later surged 13023.26% in 2025.
  • Year by year, Operating Expenses stood at $485550.0 in 2023, then crashed by 72.53% to $133390.0 in 2024, then grew by 21.71% to $162345.0 in 2025, then surged by 73.19% to $281161.0 in 2026.
  • Business Quant data shows Operating Expenses for TDAC at $281161.0 in Q1 2026, $162345.0 in Q4 2025, and $213658.0 in Q3 2025.